高级检索
当前位置: 首页 > 详情页

Prognostic value of right upper mediastinal lymphadenectomy in Sweet procedure for esophageal cancer.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu 610041, China [2]Department of Thoracic Surgery, Chongqing Cancer Institute, Chongqing 400030, China
出处:
ISSN:

关键词: Esophageal squamous cell carcinoma (ESCC) lymphadenectomy sweet prognosis

摘要:
The prognostic value of the right upper mediastinal lymph node dissection (RUMLND) for patients with middle or lower thoracic esophageal squamous cell carcinoma (ESCC-MLT) is still not well established yet. Our objective is to evaluate the prognostic role of the Sweet procedure plus right upper mediastinal lymph node dissection (MS) by comparing with the Sweet procedure with standard lymph node dissection (SS) in terms of long-term survival. Totally 1,477 ESCC-MLT patients underwent radical intent surgery (186 with MS, 1,291 with SS) at our department between January 2007 and September 2013. After propensity score matching (PSM), 186 patients from each group were matched and analyzed. The 5-year survival rates in two groups were compared by detailed stratifications in terms of clinical characteristics. As for the prognostic role of RUMLND, patients treated with MS tended to obtain higher 5-year survival rate than patients treated with SS in univariate analysis (48.1% vs. 37.4%). Moreover, in multivariate analysis, MS yielded significant higher 5-year survival rate compared with SS (P=0.041). In addition, subgroup analyses of the survival between the MS and SS patients by detailed stratifications demonstrated the survival superiority in the MS group with age <60 years old, TNM stage III, number of lymph node dissection (LND) ≥15, as well as no using of postoperative adjuvant treatment. The RUMLND in Sweet procedure is an independent prognostic factor for ESCC-MLT patients, especially for those with thoracic middle segment-located tumor, stage III or younger.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 呼吸系统
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 呼吸系统
第一作者:
第一作者机构: [1]Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu 610041, China [2]Department of Thoracic Surgery, Chongqing Cancer Institute, Chongqing 400030, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu 610041, China [*1]Department of Thoracic Surgery, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy [2]Gene set enrichment analysis and meta-analysis to identify six key genes regulating and controlling the prognosis of esophageal squamous cell carcinoma [3]A phase III trial in progress comparing tislelizumab plus concurrent chemoradiotherapy (cCRT) with placebo plus cCRT in patients with localized esophageal squamous cell carcinoma (ESCC) [4]The Prognostic Value of Peripheral Benzodiazepine Receptor in Patients with Esophageal Squamous Cell Carcinoma [5]Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy [6]Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair-associated signature [7]Prognostic role of initial pan-endoscopic tumor length at diagnosis in operable esophageal squamous cell carcinoma undergoing esophagectomy with or without neoadjuvant concurrent chemoradiotherapy [8]The impact of adjuvant therapy on survival for node-negative esophageal squamous cell carcinoma: a propensity score-matched analysis [9]Prospective Randomized Phase 2 Study of Concurrent Chemoradiation Therapy (CCRT) Versus Chemotherapy Alone in Stage IV Esophageal Squamous Cell Carcinoma (ESCC) [10]Reliability and safety of minimally invasive esophagectomy after neoadjuvant chemoradiation: a retrospective study

资源点击量:43364 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号